Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors

BACKGROUND: Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs against solid tumors. This is the first study to analyze cytotoxic ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalinovsky, Daniel V, Kibardin, Alexey V, Kholodenko, Irina V, Svirshchevskaya, Elena V, Doronin, Igor I, Konovalova, Mariya V, Grechikhina, Maria V, Rozov, Fedor N, Larin, Sergey S, Deyev, Sergey M, Kholodenko, Roman V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240879/
https://www.ncbi.nlm.nih.gov/pubmed/35764367
http://dx.doi.org/10.1136/jitc-2022-004646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240879/
https://www.ncbi.nlm.nih.gov/pubmed/35764367
http://dx.doi.org/10.1136/jitc-2022-004646

Ejemplares similares